10-Q: Claritev Q2 2025: Revenue Rises, Net Loss Narrows

Claritev Corporation reported a narrower net loss and increased revenues in Q2 2025, driven by growth in Network-Based Services and the absence of prior year's goodwill impairment.

Summary

• Net loss significantly narrowed to $(62.6) million for the three months ended June 30, 2025, compared to $(576.7) million for the same period in 2024.
• Total revenues increased by 3.5% to $241.6 million for the three months ended June 30, 2025, and by 1.1% to $472.9 million for the six months ended June 30, 2025.
• Network-Based Services revenue grew by 18.4% to $54.1 million in the three months ended June 30, 2025, primarily due to the Property and Casualty service line.
• Analytics-Based Services revenue decreased by 1.8% to $157.0 million in the three months ended June 30, 2025, mainly due to customer and program attrition.
• Payment and Revenue Integrity Services revenue increased by 9.4% to $30.5 million in the three months ended June 30, 2025, driven by Clinical Review and Payment Accuracy product lines.
• Operating income was $16.6 million for the three months ended June 30, 2025, a significant improvement from an operating loss of $(523.9) million in the prior year, largely due to no goodwill impairment in the current period.
• Interest expense increased by 22.9% to $99.7 million in the three months ended June 30, 2025, primarily due to PIK interest recognized on new notes.
• Potential medical cost savings identified totaled $6.3 billion for the three months ended June 30, 2025, up 1.9% from $6.2 billion in the prior year.
• The company completed a Refinancing Transaction on January 30, 2025, exchanging existing notes for new term loans and notes, and establishing a new $350 million revolving credit facility.
• Cash and cash equivalents were $56.4 million as of June 30, 2025, with $263.6 million loan availability under the revolving credit facility.

Sentiment

Score: 6

Explanation: The company showed significant improvement in net loss and operating income compared to the prior year, largely due to the absence of goodwill impairment. Revenue growth, while modest, is positive, and the debt refinancing provides some stability. However, the company still reports a net loss, has substantial debt, and faces increasing interest expenses and general & administrative costs. The international expansion is a strategic positive, but overall, it's a mixed bag of progress and ongoing challenges.

Positives

• Net loss significantly narrowed to $(62.6) million for the three months ended June 30, 2025, compared to $(576.7) million for the same period in 2024.
• Operating income improved to $16.6 million for the three months ended June 30, 2025, from an operating loss of $(523.9) million in the prior year, primarily due to the absence of goodwill and intangible asset impairment charges.
• Total revenues increased by 3.5% to $241.6 million for the three months ended June 30, 2025, and by 1.1% to $472.9 million for the six months ended June 30, 2025.
• Network-Based Services revenue grew by 18.4% to $54.1 million in the three months ended June 30, 2025, driven by the Property and Casualty service line.
• Payment and Revenue Integrity Services revenue increased by 9.4% to $30.5 million in the three months ended June 30, 2025.
• Potential medical cost savings identified increased by 1.9% to $6.3 billion for the three months ended June 30, 2025.
• Successfully completed a Refinancing Transaction on January 30, 2025, restructuring significant portions of long-term debt.
• Initiated first international market expansion into the Middle East and North Africa (MENA) region through a strategic partnership with Claims Care Revenue Cycle Management LLC.

Negatives

• The company reported a net loss of $(62.6) million for the three months ended June 30, 2025, and $(134.0) million for the six months ended June 30, 2025.
• Interest expense increased by 22.9% to $99.7 million for the three months ended June 30, 2025, primarily due to PIK interest on new notes.
• General and administrative expenses increased significantly by 53.2% to $52.9 million for the three months ended June 30, 2025, due to transformation costs, asset disposal losses, and increased personnel and stock compensation expenses.
• Analytics-Based Services revenues decreased by 1.8% for the three months ended June 30, 2025, primarily related to customer and program attrition.
• Cash flows from operating activities decreased by $37.0 million for the six months ended June 30, 2025, compared to the prior year, due to lower earnings (adjusted for non-cash items) and unfavorable changes in working capital.
• Shareholders' equity is a deficit of $(39.9) million as of June 30, 2025.
• Total long-term debt remains substantial at $4.53 billion as of June 30, 2025.

Risks

• Loss of clients, particularly largest clients, could materially adversely affect results of operations.
• Ability to achieve the goals of strategic plans and recognize anticipated strategic, operational, growth, and efficiency benefits when expected.
• Ability to enter new lines of business and broaden the scope of services.
• Loss of key members of the management team or inability to maintain sufficient qualified personnel.
• Ability to continue to attract, motivate, and retain a large number of skilled employees, and adapt to the effects of inflationary pressure on wages.
• Trends in the U.S. healthcare system, including recent trends of reduced healthcare utilization and increased patient financial responsibility for services.
• Effects of competition and pricing pressure.
• The inability of clients to pay for services.
• Adverse outcomes related to litigation or governmental proceedings, including ongoing antitrust lawsuits alleging conspiracy to suppress out-of-network reimbursements.
• Interruptions or security breaches of information technology systems and other cybersecurity attacks.
• Ability to maintain the licenses or right of use for the software used.
• Ability to protect proprietary information, processes, and applications.
• Inability to expand network infrastructure or preserve/increase existing market share or the size of preferred provider organization (PPO) networks.
• Decreases in discounts from providers.
• Pressure to limit access to preferred provider networks.
• Changes in the regulatory environment, including healthcare law and regulations, and the expansion of privacy and security laws.
• Heightened enforcement activity by government agencies.
• Ability to obtain additional financing or pay interest and principal on notes and other indebtedness.
• Lowering or withdrawal of credit ratings.
• Changes in accounting principles or the incurrence of impairment charges.
• Risks associated with international expansion, including difficulties managing foreign operations, operating in new markets, complying with U.S. and international laws (e.g., Foreign Corrupt Practices Act), changes in foreign rules and regulations, political/economic instability, and fluctuations in foreign currency exchange rates.

Future Outlook

The company is evaluating the provisions of the H.R.1, One Big Beautiful Bill Act (OBBBA) and its potential impacts on financial statements starting in Q3 2025. Future liquidity needs are expected to be met by internally generated funds and borrowing capacity under the 2025 revolving credit facility, with potential for additional financing through senior secured credit facilities, other indebtedness, or equity financings if required for strategic execution.

Management Comments

• We are a leading provider of data-driven cost management solutions that deliver transparency and promote fairness, quality and affordability to the healthcare industry.
• We believe our solutions provide a strong value proposition to payors, their health plan customers and healthcare consumers, as well as to providers.
• Our revenue model is aligned with the interests of our customers because in most instances the fee for our services is linked to the savings we identify.
• We advanced our long-term growth strategy by initiating our first international market expansion into the Middle East and North Africa ('MENA') region through a strategic partnership with Claims Care Revenue Cycle Management LLC.

Industry Context

Claritev operates in the U.S. healthcare industry, providing data-driven cost management solutions to payors, self-insured employers, and government-sponsored health plans. The company's services address industry challenges related to transparency, fairness, quality, and affordability. The filing notes recent trends of reduced healthcare utilization and increased patient financial responsibility, which could impact the company's business. Claritev's model, where fees are linked to identified savings, aligns with customer interests in reducing medical costs.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess performance against global benchmarks or industry standards.

Corporate Governance

Legal Proceedings

• Settled litigation filed in 2014 with a dialysis company, resulting in $9.8 million recoveries from insurers in Q3 2024 and completion of settlement payment on October 7, 2024.
• Named in numerous federal lawsuits, including putative class action lawsuits, alleging violation of antitrust laws by conspiring with commercial health insurance payors to suppress out-of-network reimbursements.
• These antitrust lawsuits have been centralized in the Northern District of Illinois, with consolidated complaints filed on November 18, 2024.
• Defendants' joint motions to dismiss the consolidated antitrust complaints were granted in part and denied in part on June 3, 2025.
• Discovery in the antitrust case is ongoing, and the company intends to vigorously defend itself.

Related Party Transactions

• Incurred related party expenses of $40 thousand for the three months ended June 30, 2025, and $59 thousand for the six months ended June 30, 2025.
• These expenses are associated with a software license from Abacus Insights, Inc.
• These expenses are also associated with customer service software and captive management services from companies controlled by Hellman & Friedman LLC.
• Prepaid expenses from related parties were $22 thousand as of June 30, 2025.

Stakeholder Impact

• Shareholders: Experienced a one-for-forty reverse stock split on September 20, 2024. The company reported a net loss, impacting shareholder value. The Refinancing Transaction restructured debt, potentially affecting future financial stability and shareholder returns.
• Employees: Stock incentive plans are in place, including new cash-settled Restricted Stock Units (cRSUs). Transformation costs include personnel costs, indicating ongoing operational changes that may affect employees.
• Customers: Benefit from the company's data-driven cost management solutions, which aim to reduce medical costs and promote fairness, quality, and affordability in healthcare. The company's revenue model is aligned with customer savings.
• Creditors: Impacted by the significant Refinancing Transaction, which restructured existing debt and introduced new debt instruments with varying interest rates and maturities. The company is subject to debt covenants and aims to maintain compliance.
• Suppliers/Partners: The company engages with third-party service providers for network access and bill review, and has strategic partnerships (e.g., Claims Care, ECHO Health). Remittance delays to third-party service providers were noted.

Next Steps

• Evaluate the provisions of the H.R.1, One Big Beautiful Bill Act (OBBBA) and its potential impacts on consolidated financial statements starting in Q3 2025.
• Continue post-implementation activities for the new enterprise resource planning (ERP) system.
• Collaborate on a comprehensive product roadmap with Claims Care Revenue Cycle Management LLC for international market expansion into the MENA region.
• Transition certain offshore business processes to Claims Care.
• Vigorously defend against ongoing antitrust lawsuits.
• Pay estimated additional income tax due ($55 million to $75 million) related to Refinancing Transactions throughout the remainder of 2025.

Key Dates

Recommendation

Claritev Corporation's Q2 2025 results show a significant reduction in net loss and a return to operating income, primarily due to the absence of the prior year's large goodwill impairment. Revenue growth, though modest, is positive, particularly in Network-Based Services. The successful completion of the debt refinancing transaction is a crucial step in addressing the company's substantial debt load and provides a clearer path forward. However, the company still operates at a net loss, faces increased interest expenses due to PIK interest, and higher general and administrative costs. The ongoing antitrust litigation and the negative shareholders' equity are also concerns. While strategic initiatives like international expansion are promising, the company remains in a transitional phase with significant financial challenges. A 'hold' recommendation is appropriate, as the positive operational shifts and debt restructuring are balanced by persistent profitability issues and high leverage, suggesting a wait-and-see approach for further clarity on sustained improvement.

Keywords

Healthcare Cost Management, SEC Filing, 10-Q, Financial Results, Revenue Integrity, Analytics-Based Services, Network-Based Services, Debt Refinancing, Healthcare Technology, Medical Cost Savings, Corporate Finance, Quarterly Report, CTEV, Claritev